SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment for infectious disease, but the situation is exceptional. “Our technology works based on chemical structure and we are looking for products available on the market that could block the protease that the virus needs to be able to replicate,” Raúl explains.
Thus, the company found three compounds with the potential to stop the virus: an investigational compound for the treatment of hyperlipidemia, another in development for some types of cancer, and a third, the one that seems the most promising, the Eravacycline TP-434, an antibiotic already approved made with tetracycline.
Now, Raúl explains, they are looking for patients to start Clinical Trial with the pharmaceutical product. Considering that in Spain, the number of hospitalized patients has greatly reduced in recent weeks, it is not easy.